drugset / Trial / NCT02784535

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

NCT02784535

RandomizedCrossoverQuadruple-blindTreatment

Summary

Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic hypotension are scarce and not effective. If left untreated, these patients have the highest risk of syncope, falls and fall-related injuries. The proposed study will determine the clinical benefit of a commercially available drug, atomoxetine, to reduce symptoms associated with neurogenic orthostatic hypotension in patients with autonomic failure.

Timeline

Start
2016-08-29
Primary completion
2021-05-12
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 10 mg
Comparator Atomoxetine Other / unclassified 18 mg